IE32343L - Powder composition - Google Patents

Powder composition

Info

Publication number
IE32343L
IE32343L IE680898A IE89868A IE32343L IE 32343 L IE32343 L IE 32343L IE 680898 A IE680898 A IE 680898A IE 89868 A IE89868 A IE 89868A IE 32343 L IE32343 L IE 32343L
Authority
IE
Ireland
Prior art keywords
medicament
particle size
carrier
powder
effective particle
Prior art date
Application number
IE680898A
Other versions
IE32343B1 (en
Original Assignee
Fisons Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Pharmaceuticals Ltd filed Critical Fisons Pharmaceuticals Ltd
Priority to IE163/73A priority Critical patent/IE32872B1/en
Publication of IE32343L publication Critical patent/IE32343L/en
Publication of IE32343B1 publication Critical patent/IE32343B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Abstract

1,242,211. Powder compositions for inhalation. FISONS PHARMACEUTICALS Ltd. 23 July, 1968 [8 Aug., 1967], No. 36270/67. Heading A5B. A pharmaceutical powder composition for inhalation comprises a mixture of a solid finely divided medicament having an effective particle size in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water-soluble carrier having an effective particle size in the range 30-80 microns. The composition is preferably substantially free of particles having effective particle sizes in the range 11-29 microns. The medicament may be diluted with a solid pharmaceutically acceptable watersoluble diluent of the same effective particle size. The diluent or carrier may be dextran, mannitol or lactose preferably crystalline lactose. The medicament may be an antianaphylactic agent such as sodium chromoglycate, a sympathomimetic amine such as isoprenaline or ephedrine, an antibiotic such as penicillin or tetracycline, a steroid, enzyme, vitamin, antihistamine or mucolytic such as N- acetyl cysteine. A preferred composition contains sodium chromoglycate and isoprenaline sulphate. The surface characteristics of the medicament or carrier particles may have been modified by crystallisations, spray drying, precipitation or by coating with a pharmaceutically acceptable material, e.g. stearic acid or polyvinyl pyrrolidone (which coating may give the medicament sustained release action). The powder may be contained in a capsule, e.g. of gelatin or plastic, which is pierced for administration. The powder may be administered as a dispersion in an air stream obtained by simultaneous rotation and vibration of the pierced capsule. The composiitons are prepared by mixing together, preferably in a stirred mixer, the medicament and carrier, which if necessary have been subjected to comminution and particle size classification prior to mixing. [GB1242211A]
IE898/68A 1967-08-08 1968-07-25 Pharmaceutical composition IE32343B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IE163/73A IE32872B1 (en) 1967-08-08 1968-07-25 Drug for use in pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
IE32343L true IE32343L (en) 1969-02-08
IE32343B1 IE32343B1 (en) 1973-06-27

Family

ID=10386572

Family Applications (1)

Application Number Title Priority Date Filing Date
IE898/68A IE32343B1 (en) 1967-08-08 1968-07-25 Pharmaceutical composition

Country Status (14)

Country Link
US (1) US3634582A (en)
JP (1) JPS5643448B1 (en)
BE (1) BE718846A (en)
CA (1) CA946280A (en)
DE (2) DE1792799A1 (en)
DK (1) DK123276B (en)
FI (1) FI48973C (en)
FR (2) FR8142M (en)
GB (1) GB1242211A (en)
IE (1) IE32343B1 (en)
MY (2) MY7400330A (en)
NL (1) NL161984C (en)
NO (1) NO128307B (en)
SE (1) SE372420B (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (en) * 1971-08-06 1973-02-02 Beecham Group Ltd COMPOSITION FOR THE TREATMENT OF ASTHMA
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (en) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Use of corticosteroid active ingredients for inhalation therapy
DE2535258C2 (en) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalable drug in pellet form
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
CY1333A (en) * 1980-04-30 1986-10-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
BE891013A (en) * 1980-11-05 1982-05-05 Fisons Ltd PHARMACEUTICAL COMPOSITIONS
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
EP0309519B1 (en) * 1987-04-09 1992-07-08 FISONS plc Pharmaceutical compositions containing pentamidine
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
EP0721331B1 (en) * 1993-10-01 2001-12-05 AstraZeneca AB Process i
IS1736B (en) 1993-10-01 1999-12-30 Astra Ab Methods and devices that promote increased particle aggregation
NL9301851A (en) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablation catheter.
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
EP0806945B1 (en) 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AU730843B2 (en) * 1997-05-27 2001-03-15 Direct-Haler A/S Inhaler for powdered medicaments
PL200940B1 (en) * 1998-08-18 2009-02-27 Univ California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
ITMI991582A1 (en) 1999-07-16 2001-01-16 Chiesi Farma Spa DUST CONSTITUTED FROM PARTICLES HAVING THE PERFECTLY SMOOTH SURFACE FOR USE AS VEHICLES FOR THE PREPARATION OF INALA MIXTURES
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
BR0107304A (en) * 2000-10-12 2002-08-13 Boehringer Ingelheim Pharma Inhalation powder containing tiotropium
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
EP1487417A4 (en) * 2001-09-17 2010-03-17 Glaxo Group Ltd Dry powder medicament formulations
WO2003043574A2 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (en) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
JP2006516531A (en) * 2002-08-21 2006-07-06 ノートン ヘルスケアー リミテッド Inhalation composition
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (en) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New tiotropium-containing powder formulation for inhalation
DE10317461A1 (en) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338399A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
DE10338407A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
ATE498394T1 (en) 2003-09-02 2011-03-15 Norton Healthcare Ltd METHOD FOR PRODUCING A MEDICATION
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CA2562386C (en) 2004-04-21 2014-11-18 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
AR050902A1 (en) 2004-04-27 2006-12-06 Glaxo Group Ltd QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
DE102004048389A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modification of surfaces of lactose as adjuvant for use with powder inhalants
DE102004048390A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New powder inhalants based on modified lactose mixtures as adjuvant
BRPI0606364A2 (en) * 2005-02-10 2010-03-23 Glaxo Group Ltd process for forming lactose suitable for use in a pharmaceutical formulation
JP2011529135A (en) 2008-07-24 2011-12-01 レール・リキード−ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード Heteroleptic cyclopentadienyl transition metal precursor for the deposition of transition metal containing films
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
LT2400950T (en) 2009-02-26 2019-08-26 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PT106094A (en) 2012-01-13 2013-07-15 Hovione Farmaciencia S A ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
JP6499077B2 (en) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション Combination therapy for the treatment of Alzheimer's disease and related diseases
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
MX2016004530A (en) 2013-10-08 2017-02-13 Lam Therapeutics Inc Rapamycin for the treatment of lymphangioleiomyomatosis.
CN106102737B (en) 2013-10-22 2019-06-14 综合医院公司 Cromoglycic acid derivative and the correlation technique of imaging and treatment
ES2952025T3 (en) 2014-04-04 2023-10-26 Ai Therapeutics Inc An inhalable rapamycin formulation to treat age-related conditions
MX2017004440A (en) 2014-10-07 2017-11-01 Lam Therapeutics Inc An inhalable rapamycin formulation for the treatment of pulmonary hypertension.
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MX2019014671A (en) * 2017-06-28 2020-02-07 Philip Morris Products Sa Container with particles for use with inhaler.
CA3070386A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP2021529771A (en) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション Powder formulation of sodium chromoline and α-lactose
EP3910324A1 (en) 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
EP4203945A1 (en) 2020-08-28 2023-07-05 Universität Linz Use of leoligin in the prevention of tissue damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (en) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri TRANSPORTABLE GARDEN SWIMMING POOL OR POOL WITH WALLS MADE OF PLASTIC FOIL.
FR1489749A (en) 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Process for the preparation of bis-chromonyl compounds and their derivatives

Also Published As

Publication number Publication date
DE1792207B2 (en) 1977-10-13
DE1792799A1 (en) 1977-08-11
CA946280A (en) 1974-04-30
FR8142M (en) 1970-08-17
MY7400330A (en) 1974-12-31
DE1792207C3 (en) 1978-06-29
JPS5643448B1 (en) 1981-10-13
FI48973C (en) 1975-03-10
NO128307B (en) 1973-10-29
FR1605538A (en) 1979-02-23
DE1792207A1 (en) 1971-11-04
MY7400329A (en) 1974-12-31
NL161984B (en) 1979-11-15
US3634582A (en) 1972-01-11
FI48973B (en) 1974-12-02
SE372420B (en) 1974-12-23
NL161984C (en) 1980-04-15
GB1242211A (en) 1971-08-11
IE32343B1 (en) 1973-06-27
NL6811060A (en) 1969-02-11
BE718846A (en) 1969-01-31
DK123276B (en) 1972-06-05

Similar Documents

Publication Publication Date Title
IE32343L (en) Powder composition
JP2974409B2 (en) Particulate drug composition
Zeng et al. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro
CA2124568C (en) Method for producing microgranulated particle
US3882228A (en) Analgesic formulations
JP2550362B2 (en) Spray dried acetaminophen
MX9404762A (en) COMPOSITIONS FOR INHALATION AND PROCESS FOR ITS PREPARATION.
US4757090A (en) Direct tableting acetaminophen compositions
GB1381872A (en) Pharmaceutical compositions for inhalation
IE60652B1 (en) Spray dried ibuprofen
CA2125685A1 (en) Powders for inhalation and process for preparing them
KR880013560A (en) Pharmaceutical composition
HU225964B1 (en) Moisture barrier film coating composition, method, and coated form
CA2430318A1 (en) Powder formulation and method for producing the same
EP0203768A2 (en) A therapeutic effervescent composition and a method of preparing the same
EP0834314A1 (en) Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
KR20000070189A (en) New Formulation for Inhalation Having a Poured Bulk Density of from 0.28 to 0.38 g/㎖, Comprising Terbutaline Sulphate, a Process for Preparing the Formulation and the Use Thereof
JPS63112519A (en) Production of nifedipine preparation
JP5034226B2 (en) Solid formulation with stabilized ingredients
GB644081A (en) Improvements in pectin products and the process of making same
JPH0967247A (en) Production of medicinal preparation of uniformly fine particle
GB1511852A (en) Reconstitutable powders
GB1468815A (en) Pharmaceutical compositions
JPS6271552A (en) Fine granulation of organic compound
CA2313629C (en) Method for transferring one or more active ingredients between different phase carriers